Different senescent cell types express different anti-apoptotic survival proteins. Adipose senescent cells rely on BCL-2; epithelial senescent cells rely on src kinase; muscle senescent cells rely on BCL-W and BCL-XL. A comprehensive senolytic stack covers these distinct survival pathways through complementary agents.

Should I start all agents simultaneously?

No. Start with one agent (fisetin or quercetin), evaluate tolerance for 1–2 cycles, then layer in additional agents. This allows attribution of any effects or side effects.

Is there a maximum number of senolytics I can combine?

No hard limit, but practical complexity increases with each addition. Three agents (fisetin + quercetin + spermidine) covers most mechanisms efficiently. Adding a fourth (dasatinib) requires physician oversight.